Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06800742
Recruiting Observational

Body Composition in Adolescents With Anorexia Nervosa

NCT06800742 · tracked via the Priya Life Science Italy tracker
Sponsor
Istituto Auxologico Italiano
Phase
Observational
Started
2024-07-12
Last updated
2026-03-30

Condition(s) studied

Anorexia Nervosa

Investigational drug(s) / intervention(s)

Collection of anthropometric and biochemical parameters

Collection of anthropometric and biochemical parameters: Collection of anthropometric parameters biochemical parameters basal metabolic rate body composition questionnaires

Study summary

Body Mass Index (BMI) is currently the most widely recommended parameter for identifying underweight subjects. Among eating disorder diseases, anorexia nervosa (AN) is the one with the highest mortality rate and with relapses between 12 and 27%. To date, recovery programs allow approximately 40% of subjects to achieve recovery, 30% demonstrate improvements, and 20% remain chronically affected. These data demonstrate the importance of continuously monitoring changes in weight and body composition of these subjects. Bioelectrical impedance (BIA) is widely used to determine body composition in AN. BIA provides various parameters, such as lean mass (LM), fat mass (FM), total body water (TBW), and phase angle (PhA). Among these parameters, in addition to LM and FM, PhA has also been used to characterize underweight subjects with AN. In addition to the observed relationship between PhA and body composition in individuals with AN, PhA has also been related to the basal metabolic rate (BMR). BMR undergoes changes mainly due to loss of muscle mass and a significant reduction in BMR has been observed in AN subjects. Finally, physical activity represents a significant determinant of body composition and can help regulate BMR.

Therefore, monitoring changes in body composition (LM, FM, and PhA) and indirect indices (lean mass index and fat mass index) using BIA, together with monitoring changes in BMR and physical activity level, could provide important support for the continuous control and definition of the clinical stage of the disease in patients with AN.

The aim of this study is to determine body composition, basal metabolic rate, and level of physical activity in Anorexia Nervosa and normal weight subjects to identify the most consistent parameters to define the clinical stage of the disease in subjects with AN.

Eligibility

Sex
FEMALE
Min age
12 Years
Max age
18 Years
Healthy volunteers
No
Adolescents with Anorexia Nervosa: Inclusion Criteria: * Female sex * Age range: 12-18 years * Anorexia nervosa * Hospitalized at the Division of Auxologia, San Giuseppe Hospital, Istituto Auxologico Italiano, IRCCS, Piancavallo, Italy Exclusion Criteria: * Absence of signed informed consent Adolescents with normal weight: Inclusion Criteria: * Female sex * Age range: 12-18 years * Normal weight Exclusion Criteria: * Absence of signed informed consent

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Istituto Auxologico Italiano IRCCS, Site Piancavallo Oggebbio Verbania Recruiting

More Istituto Auxologico Italiano trials in Italy

Gait and Balance Impairment in Rare and Very Rare Neurological Diseases Recruiting
LONgitudinal and Integrated Evaluation of Biomarkers in reLation to phenotYpe in ALS Recruiting
Global Approach to Faint and Falls Recruiting
The FUnctional TricUspid REgurgitation by 3D EChocardiography Cooperative Study Recruiting
Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study Recruiting

Other trials for the same condition

AI and VR Devices for Eating Behavior Rehabilitation Recruiting
Virtual Reality Exposure to Reduce Food Related Anxiety in Anorexia Nervosa Recruiting
Intermittent Theta Burst Transcranial Magnetic Stimulation of the Right Parietal Lobe in Anorexia Nervosa Starting soon
Sphingolipidomic Profile in Anorexia Nervosa Recruiting
Posture and Spinal Mobility in Anorexia Nervosa Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06800742 on ClinicalTrials.gov ↗ ← All trials in Italy